News

  • 3 October 2019

    Keytruda approved in China as a monotherapy for NSCLC

    Merck has announced that Keytruda has been approved by the Chinese National Medical Products Administration (NMPA) as a monotherapy for first-line treatment of local advanced or metastatic non-small cell lung...

Close
Close
Close

Go Top